BIOGEN INC. Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
BIOGEN INC. (BIIB) had Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net of $144.70 million as of 2017-02-01, per its 10-K filed 2019-02-06.
Discontinued › Balance Sheet › Assets › Assets, Current › Disposal Group, Including Discontinued Operation, Assets, Current
us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet · last filed 2019-02-06
- 2017-02-01: Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net $144.70M.
| Period end | Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net |
|---|---|
| 2017-02-01 | $144.70M 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |